Add to ORKG血管紧张素受体阻断剂(ARB)在受体水平阻断肾素-血管紧张素-醛固酮系统(RAAS)、逆转血管重构和心肌肥厚,为临床心力衰竭(HF)治疗提供了新的选择.本文回顾分析相关循证研究资料,综述ARB治疗HF的优势和不足.中国医药卫生事业发展基金中国科技核心期刊(ISTIC)010582-5853
心力衰竭(heart failure,HF)包括射血分数降低HF(即收缩性心力衰竭)和射血分数保留HF(即舒张性心力衰竭).标准化药物,如血管紧张素转换酶抑制剂 (angiotensin conver...
Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents wh...
Collectively, a series of large, prospective randomised outcome trials has now shown that angiotensi...
心肌梗死在心血管事件链中占有重要地位,随着抗高血压药物-血管紧张素Ⅱ受体拮抗剂(ARB)的临床研究和不断发展,越来越多的医生与患者提出疑问,心肌梗死患者是否也能从ARB药物中获益,因此,本文从循证医学...
血管紧张素Ⅱ拮抗药物(包括血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂)已在临床得到广泛使用,尽管安全性相对较好,但仍会出现不良反应,而且医生对其仍缺乏足够认识.本文对其作用机制、主要不良反应及其防治...
目的:评价利尿剂联合β受体阻滞剂(β-RB)治疗慢性心力衰竭(CHF)的临床疗效.方法:将127例CHF患者随机分为三组,分别以利尿剂(A组)、β-RB(B组)和利尿剂+β-RB(C组)治疗,比较各组...
过去的5～10年中,血管紧张素受体拮抗剂(ARB)已经确立了其作为有效抗高血压药物的地位.中文核心期刊要目总览(PKU)中国科学引文数据库(CSCD)0251732-17338
The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment o...
Background: The efficacy and safety of adding an angiotensin receptor blocker (ARB) in heart failure...
The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment o...
The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment o...
Angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers are main stream of pharmacological...
Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents wh...
目的通过对左室结构参数、血液动力学参数、心功能级别改善及副作用发生率等指标进行比较,探讨血管紧张素转化酶抑制剂(angiotensin-converting enzyme inhibitor,ACEI...
Large-scale, placebo-controlled, randomized clinical trials have demonstrated that angiotensin-conve...
心力衰竭(heart failure,HF)包括射血分数降低HF(即收缩性心力衰竭)和射血分数保留HF(即舒张性心力衰竭).标准化药物,如血管紧张素转换酶抑制剂 (angiotensin conver...
Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents wh...
Collectively, a series of large, prospective randomised outcome trials has now shown that angiotensi...
心肌梗死在心血管事件链中占有重要地位,随着抗高血压药物-血管紧张素Ⅱ受体拮抗剂(ARB)的临床研究和不断发展,越来越多的医生与患者提出疑问,心肌梗死患者是否也能从ARB药物中获益,因此,本文从循证医学...
血管紧张素Ⅱ拮抗药物(包括血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂)已在临床得到广泛使用,尽管安全性相对较好,但仍会出现不良反应,而且医生对其仍缺乏足够认识.本文对其作用机制、主要不良反应及其防治...
目的:评价利尿剂联合β受体阻滞剂(β-RB)治疗慢性心力衰竭(CHF)的临床疗效.方法:将127例CHF患者随机分为三组,分别以利尿剂(A组)、β-RB(B组)和利尿剂+β-RB(C组)治疗,比较各组...
过去的5～10年中,血管紧张素受体拮抗剂(ARB)已经确立了其作为有效抗高血压药物的地位.中文核心期刊要目总览(PKU)中国科学引文数据库(CSCD)0251732-17338
The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment o...
Background: The efficacy and safety of adding an angiotensin receptor blocker (ARB) in heart failure...
The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment o...
The renin-angiotensin-aldosterone system is a well-established therapeutic target in the treatment o...
Angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers are main stream of pharmacological...
Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents wh...
目的通过对左室结构参数、血液动力学参数、心功能级别改善及副作用发生率等指标进行比较,探讨血管紧张素转化酶抑制剂(angiotensin-converting enzyme inhibitor,ACEI...
Large-scale, placebo-controlled, randomized clinical trials have demonstrated that angiotensin-conve...
心力衰竭(heart failure,HF)包括射血分数降低HF(即收缩性心力衰竭)和射血分数保留HF(即舒张性心力衰竭).标准化药物,如血管紧张素转换酶抑制剂 (angiotensin conver...
Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents wh...
Collectively, a series of large, prospective randomised outcome trials has now shown that angiotensi...